Bethesda, MD 20892, (301) 402–4128, mark.vosvick@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 9, 2021.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–03019 Filed 2–12–21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-Day Comment Request; CTEP Branch and Support Contracts Forms and Surveys (National Cancer Institute)

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

DATES: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this

notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function.

FOR FURTHER INFORMATION CONTACT:

Michael Montello, Pharm. D., Cancer Therapy Evaluation Program (CTEP), 9609 Medical Center Drive, MSC 9742, Rockville, MD 20850 or call non-toll-free number 240–276–6080 or Email your request, including your address to: montellom@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This proposed information collection was previously published in the Federal Register on October 8, 2020, page 63565 (Vol. 85, No. 196, FR 63565) and allowed 60 days for public comment. No public comments were received. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

Proposed Collection Title: CTEP Support Contract Forms and Surveys (NCI), OMB #0925–0753 Expiration Date 07/31/2021, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH).

Need and Use of Information Collection: The National Cancer

Institute (NCI) Cancer Therapy Evaluation Program (CTEP) and the Division of Cancer Prevention (DCP) fund an extensive national program of cancer research, sponsoring clinical trials in cancer prevention, symptom management and treatment for qualified clinical investigators. As part of this effort, CTEP implements programs to register clinical site investigators and clinical site staff, and to oversee the conduct of research at the clinical sites. CTEP and DCP also oversee two support programs, the NCI Central Institutional Review Board (CIRB) and the Cancer Trial Support Unit (CTSU). The combined systems and processes for initiating and managing clinical trials is termed the Clinical Oncology Research Enterprise (CORE) and represents an integrated set of information systems and processes which support investigator registration, trial oversight, patient enrollment, and clinical data collection. The information collected is required to ensure compliance with applicable federal regulations governing the conduct of human subjects research (45 CFR 46 and 21 CRF 50), and when CTEP acts as the Investigational New Drug (IND) holder, FDA regulations pertaining to the sponsor of clinical trials and the selection of qualified investigators under 21 CRF 312.53). Survey collections assess satisfaction and provide feedback to guide improvements with processes and technology.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 151,792.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
CTSU IRB/Regulatory Approval Transmittal Form (Attachment A01).	Health Care Practitioner	2,444	12	2/60	978
CTSU IRB Certification Form (Attachment A02)	Health Care Practitioner	2,444	12	10/60	4,888
Withdrawal from Protocol Participation Form (Attachment A03).	Health Care Practitioner	279	1	10/60	47
Site Addition Form (Attachment A04)	Health Care Practitioner	80	12	10/60	160
CTSU Request for Clinical Brochure (Attachment A06).	Health Care Practitioner	360	1	10/60	60
CTSU Supply Request Form (Attachment A07)	Health Care Practitioner	90	12	10/60	180
RTOG 0834 CTSU Data Transmittal Form (Attachment A10).	Health Care Practitioner	12	76	10/60	152
CTSU Patient Enrollment Transmittal Form (Attachment A15).	Health Care Practitioner	12	12	10/60	24
CTSU Transfer Form (Attachment A16)	Health Care Practitioner	360	2	10/60	120
CTSU System Access Request Form (Attachment A17).	Health Care Practitioner	180	1	10/60	30
CTSU OPEN Rave Request Form (Attachment A18).	Health Care Practitioner	30	21	10/60	105

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
CTSU LPO Form Creation (Attachment A19) CTSU Site Form Creation (Attachment A20) CTSU Electronic Signature Form (Attachment	Health Care Practitioner Health Care Practitioner Health Care Practitioner	5 400 400	2 10 10	120/60 30/60 10/60	20 2,000 667
A21). NCI CIRB AA & DOR between the NCI CIRB	Participants	50	1	15/60	13
and Signatory Institution (Attachment B01). NCI CIRB Signatory Enrollment Form (Attach-	Participants	50	1	15/60	13
ment B02). CIRB Board Member Application (Attachment	Board Member	100	1	30/60	50
B03). CIRB Member COI Screening Worksheet (At-	Board Members	100	1	15/60	25
tachment B08). CIRB COI Screening for CIRB meetings (Attach-	Board Members	72	1	15/60	18
ment B09). CIRB IR Application (Attachment B10) CIRB IR Application for Exempt Studies (Attach-	Health Care Practitioner Health Care Practitioner	80 4	1 1	60/60 30/60	80 2
ment B11). CIRB Amendment Review Application (Attach-	Health Care Practitioner	400	1	15/60	100
ment B12). CIRB Ancillary Studies Application (Attachment	Health Care Practitioner	1	1	60/60	1
B13). CIRB Continuing Review Application (Attachment	Health Care Practitioner	400	1	15/60	100
B14). Adult IR of Cooperative Group Protocol (Attach-	Board Members	65	1	180/60	195
ment B15). Pediatric IR of Cooperative Group Protocol (At-	Board Members	15	1	180/60	45
tachment B16). Adult Continuing Review of Cooperative Group	Board Members	275	1	60/60	275
Protocol (Attachment B17). Adult Amendment of Cooperative Group Protocol	Board Members	40	1	120/60	80
(Attachment B19). Pediatric Amendment of Cooperative Group Pro-	Board Members	25	1	120/60	50
tocol (Attachment B20). Pharmacist's Review of a Cooperative Group	Board Members	50	1	120/60	100
Study (Attachment B21). Adult Expedited Amendment Review (Attachment	Board Members	348	1	30/60	174
B23). Pediatric Expedited Amendment Review (Attach-	Board Members	140	1	30/60	70
ment B24). Adult Expedited Continuing Review (Attachment	Board Members	140	1	30/60	70
B25). Pediatric Expedited Continuing Review (Attach-	Board Members	36	1	30/60	18
ment B26). Adult Cooperative Group Response to CIRB Re-	Health Care Practitioner	30	1	60/60	30
view (Attachment B27). Pediatric Cooperative Group Response to CIRB	Health Care Practitioner	5	1	60/60	5
Review (Attachment B28). Adult Expedited Study Chair Response to Re-	Board Members	40	1	30/60	20
quired Modifications (Attachment B29). Reviewer Worksheet—Determination of UP or SCN (Attachment B31).	Board Members	400	1	10/60	67
Reviewer Worksheet—CIRB Statistical Reviewer Form (Attachment B32).	Board Members	100	1	15/60	25
CIRB Application for Translated Documents (Attachment B33).	Health Care Practitioner	100	1	30/60	50
Reviewer Worksheet of Translated Documents (Attachment B34).	Board Members	100	1	15/60	25
Reviewer Worksheet of Recruitment Material (Attachment B35).	Board Members	20	1	15/60	5
Reviewer Worksheet Expedited Study Closure Review (Attachment B36).	Board Members	20	1	15/60	5
Reviewer Worksheet of Expedited IR (Attachment B38).	Board Members	5	1	30/60	3
Annual Signatory Institution Worksheet About Local Context (Attachment B40).	Health Care Practitioner	400	1	40/60	267
Annual Principal Investigator Worksheet About Local Context (Attachment B41).	Health Care Practitioner	1,800	1	20/60	600
Study-Specific Worksheet About Local Context (Attachment B42).	Health Care Practitioner	4,800	1	15/60	1,200

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Study Closure or Transfer of Study Review Responsibility (Attachment B43).	Health Care Practitioner	1,680	1	15/60	420
Unanticipated Problem or Serious or Continuing Noncompliance Reporting Form (Attachment B44).	Health Care Practitioner	360	1	20/60	120
Change of Signatory Institution PI Form (Attachment B45).	Health Care Practitioner	120	1	20/60	40
Request Waiver of Assent Form (Attachment B46).	Health Care Practitioner	35	1	20/60	12
CIRB Waiver of Consent Request Supplemental Form (Attachment B47).	Health Care Practitioner	20	1	15/60	5
Review Worksheet CIRB Review for Inclusion of Incarcerated Participants (Attachment B48).	Board Members	20	1	60/60	20
Notification of Incarcerated Participant Form (B49).	Health Care Practitioner	20	1	20/60	7
CTSU OPEN Survey (Attachment C03)	Health Care Practitioner Participants	10 600	1 1	15/60 15/60	3 150
Follow-up Survey (Communication Audit) (Attachment C05).	Participants/Board Members.	300	1	15/60	75
CIRB Board Member Annual Assessment Survey (Attachment C07).	Board Members	60	1	15/60	15
PIO Customer Satisfaction Survey (Attachment C08).	Health Care Practitioner	60	1	5/60	5
Audit Scheduling Form (Attachment D01)	Health Care Practitioner	152	5	21/60	266
Preliminary Audit Finding Form (Attachment D02)	Health Care Practitioner	152	5	10/60	127
Audit Maintenance Form (Attachment D03) Final Audit finding Report Form (Attachment D04).	Health Care Practitioner Health Care Practitioner	152 75	5 11	9/60 1,098/60	114 15,098
Follow-up Form (Attachment D05)	Health Care Practitioner	75	7	27/60	236
Roster Maintenance Form (Attachment D06)	Health Care Practitioner	5	1	18/60	2
Final Report and CAPA Request Form (Attachment D07).	Health Care Practitioner	12	9	1,800/60	3,240
NCI/DCTD/CTEP FDA Form 1572 for Annual Submission (Attachment E01).	Physician	26,500	1	15/60	6,625
NCI/DCTD/CTÈ Biosketch (Attachment E02)	Physician; Health Care Practitioner.	48,000	1	120/60	96,000
NCI/DCTD/CTEP Financial Disclosure Form (Attachment E03).	Physician; Health Care Practitioner.	48,000	1	15/60	12,000
NCI/DCTD/CTEP Agent Shipment Form (ASF) (Attachment E04).	Physician	24,000	1	10/60	4,000
Totals		167,715	235,670		151,792

Dated: February 1, 2021.

Diane Kreinbrink,

Project Clearance Liaison, National Cancer Institute, National Institutes of Health.

 $[FR\ Doc.\ 2021-03046\ Filed\ 2-12-21;\ 8:45\ am]$

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on March 2nd, 2021, from 10:00 a.m. EST to 4:30 p.m. EST, and March 3rd, 2021, from 10:00 a.m. EST to 4:30 p.m. EST.

The board will meet in open-session March 2nd, 2021, from 10:00 a.m. EST to 2:00 p.m. EST to discuss the Mandatory Guidelines for Federal Workplace Drug Testing Programs with updates from the Department of Transportation, the Nuclear Regulatory Commission, and the Department of Defense. Other discussion topics include an update on marijuana studies and efforts as well as the Employee Assistance Program (EAP) Toolkit. The board will meet in closed-session on March 2nd, 2021, from 2:15 p.m. EST to 4:30 p.m. EST, and March 3rd, 2021, from 10:00 a.m. EST to 4:30 p.m. EST,

to discuss confidential issues surrounding the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair), the Federal Drug-Free Workplace Programs and emerging issues, updates on the revisions of the Urine and Oral Fluid Mandatory Guidelines and the Biomarker Table, preliminary and unpublished studies from the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU), and cannabidiol (CBD) information from FDA. Therefore, the March 2nd, 2021, from 2:15 p.m. EST to 4:30 p.m. EST, and the March 3rd, 2021, from 10:00 a.m. EST to 4:30 p.m. EST, meetings are closed to the public, as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and